Regal Healthcare Capital Partners Closes RHCP IV at $610M, Above Target

TL;DR: Regal Healthcare Capital Partners closed its fourth fund, RHCP IV, at $610M in total commitments on July 7, 2026, beating its $550M target by roughly 11%, according to Regal's press release via PRNewswire. The firm has now raised nearly $1.3B since 2018 to buy lower-middle-market healthcare services businesses, and the oversubscription tells you where institutional money still wants to go even when general PE fundraising is picky.

Here is the number that should catch your attention, and it is not $610M. It is the growth rate between fund three and fund four. RHCP III closed at $415M in November 2021. RHCP IV closed at $610M less than five years later. That is roughly 47% growth, fund over fund, in a stretch when a lot of middle-market PE sponsors were happy to hold flat or shrink their next vehicle. Limited partners (LPs, the institutions and family offices that supply the capital) do not hand a manager 47% more money because they liked the holiday card. They do it because the last fund performed, the pipeline looks repeatable, and the sponsor has a strategy narrow enough to execute without drifting into deals it does not understand.

The contrarian point I want to make is this: everyone treats "healthcare PE fundraising is hot" as the headline. It is not, uniformly. 2025 was a record year for healthcare PE deal activity by dollar volume, but fundraising overall in private equity stayed selective, with LPs consolidating relationships around fewer managers rather than spreading commitments thin. Regal's oversubscribed close is not proof that healthcare fundraising is easy right now. It is proof that a specific kind of manager, one with a tightly defined thesis and a repeatable deal size, is the one still getting rewarded while generalist funds struggle to hit target. That distinction matters if you are trying to read what is actually happening in this market instead of what the press release wants you to conclude.

Fund Size Progression and Deal Mechanics

Regal Healthcare Capital Partners was founded in 2018. RHCP IV is its fourth institutional fund, and the firm has now raised close to $1.3B in aggregate commitments across all four vehicles. The fund closed at $610M in total commitments, with roughly $575M of that coming from external limited partners, above the $550M target the firm set when it launched fundraising, according to The Healthcare Investor. Lazard served as placement agent (the intermediary that runs the fundraising process and introduces the manager to LPs), and Kirkland & Ellis served as legal counsel on the close, per the firm's own announcement.

Fund	Close Date	Size	Growth vs. Prior Fund
RHCP III	November 2021	$415M	—
RHCP IV	July 7, 2026	$610M ($575M external)	~47%

The strategy itself is narrow by design. Regal targets equity checks of roughly $75M per deal into lower-middle-market healthcare services companies, generally businesses with $20M to $100M in revenue and $2M to $10M in EBITDA (earnings before interest, taxes, depreciation, and amortization, the standard cash-flow proxy used to price a deal). That is a specific enough box that the firm is not competing with the $1B-plus healthcare funds for the same targets, and it is not so small that it is fishing in the same pond as independent sponsors doing $10M deals. Publicly named portfolio companies include Thriveworks, InFocus Eyecare, and Send Health, which gives you a sense of the sub-sectors in play: behavioral health, vision care, and virtual/specialty health services rather than hospitals or health systems.

Regal's general partners include David Kim, MD, and co-founder Jon Santemma, JD, MBA. A GP roster that pairs a physician with a lawyer/MBA is common in healthcare-focused PE because sourcing and diligence in this sector require both clinical credibility with the operators you are buying from and the deal structuring chops to close a transaction cleanly. If you are ever evaluating a healthcare-focused fund manager, the GP background is one of the first things worth checking, alongside how their track record has actually performed across fund vintages, not just how the current fundraise is being marketed. For a framework on that, see AIN's guide to evaluating a fund manager's track record across fund vintages, which applies just as well to a fourth-time healthcare buyout shop as it does to a first-time venture manager.

Why Healthcare PE Fundraising Matters Right Now

Healthcare private equity had a record 2025 by deal value, with roughly $191B deployed and 445 buyouts, the second-highest deal count on record, according to Bain's Global Healthcare Private Equity Report. That volume was not evenly distributed. It concentrated in sponsors with clear theses in services categories that are fragmented enough to support a roll-up strategy: behavioral health, dental, veterinary, physical therapy, specialty pharmacy, and similar spaces where a $50M platform can absorb a string of smaller add-on acquisitions and generate multiple expansion just from scale.

That backdrop explains why Regal is not the only healthcare-focused firm posting a large close. In 2025, Ampersand closed a fund at $1.5B and Water Street closed one at $1.9B, both healthcare-focused vehicles well above Regal's size, a pattern also tracked by PitchBook's healthcare fundraising coverage. Regal's $610M sits in a different tier, deliberately, because its check size and target company profile are smaller than what those larger funds are chasing. The pattern across all three closes is the same: LPs are underwriting sponsors who can point to a specific, repeatable playbook in a sector with structural tailwinds, rather than generalist buyout funds asking for a bigger blank check.

The structural tailwind in healthcare services is not complicated. Demand is inelastic, reimbursement dynamics create fragmentation that favors consolidators with negotiating leverage over payers, and an aging population keeps volume growing independent of the broader economic cycle. None of that means every healthcare services deal works. It means the sector gives a disciplined buyer more at-bats than most.

What This Means in Practice

A fund closing above target with a placement agent as established as Lazard and counsel as established as Kirkland & Ellis tells you the deal got real institutional scrutiny before a single dollar was wired. Placement agents do not put their name on a raise that looks shaky, and large law firms do not staff a fund closing without running the fund's terms through their own risk committee. That is not a guarantee of returns. It is a signal that the process around this raise was buttoned up, which is a separate and lower bar, but a bar worth clearing nonetheless.

I want to be direct about something funds like this do not advertise: the first year or two of a new PE fund's life almost always shows a dip before it shows a gain. This is the J-curve, and it exists because a fund pays fees and makes early-stage investments before any of those investments have had time to mature and produce distributions. If you ever get exposure to a vehicle like RHCP IV, whether directly or through a fund of funds, expect reported performance to look unimpressive for the first 24 to 36 months. That is normal, not a red flag, and AIN has a full breakdown of the mechanics in our piece on the J-curve in private equity fund performance.

What You Cannot Access, and What You Can

Here is the part I will not soften. RHCP IV is a closed-end institutional fund. Its LP base is pensions, endowments, family offices, and similar large allocators writing checks that are almost certainly in the millions, subject to lockups measured in years, and gated behind accreditation and often qualified-purchaser thresholds well above standard accredited investor status. If you are an individual investor reading this hoping to wire money into RHCP IV, you cannot. The fund is not raising from retail, and it is not raising from most accredited individuals either. That door is closed, and no amount of enthusiasm about the $610M number changes that.

What you can actually access if you want healthcare-sector private capital exposure falls into a narrower set of vehicles. Publicly traded business development companies (BDCs), a fund structure regulated under the Investment Company Act and overseen by the SEC, that lend to or invest in healthcare services companies trade on exchanges and are open to any investor with a brokerage account. Interval funds and tender-offer funds, a structure that lets ordinary accredited investors buy into a semi-liquid private credit or private equity-style portfolio with periodic redemption windows rather than a hard multi-year lockup, have increasingly added healthcare services allocations as sponsors like Regal generate more deal flow that flows downstream into secondary markets. GP-led secondaries and continuation funds, where a sponsor moves a strong-performing asset out of an aging fund into a new vehicle rather than selling it outright, are another avenue institutional and some accredited investors use to get exposure to seasoned healthcare assets without waiting for a full new fundraise cycle. If that structure is unfamiliar, AIN's guide to GP-led secondaries and continuation funds walks through how LPs evaluate them.

None of these substitutes give you Regal specifically. They give you the same sector thesis, sometimes with different fee structures, different liquidity terms, and different risk profiles. Read the fine print on each before assuming they behave like the underlying fund.

Your Next Step

If you are an accredited or institutional investor with the check size and lockup tolerance this asset class actually requires, the actionable move is not chasing Regal specifically. It is building a watchlist of healthcare services-focused buyout managers with fund histories that show the same pattern Regal just showed: a fund three that performed well enough to justify a meaningfully larger fund four, a narrow and repeatable deal thesis, and institutional-grade placement and legal counsel on the raise. Ask any manager you are evaluating for net IRR (internal rate of return, the annualized return after fees) and net MOIC (multiple on invested capital, total value returned divided by capital invested) on prior funds, not just gross figures, and ask how much of the prior fund's capital is already realized versus still marked at cost. If you do not have direct fund access, start with the BDC and interval fund route, verify the manager's healthcare allocation and fee load before committing capital, and treat the first 24 months of any new private allocation as a J-curve, not a verdict.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.